Salute e Benessere

Department of Health - Abu Dhabi, M42 and AbbVie enter a strategic partnership…

The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. DoH seeks to drive research that will contribute to policy changes and guideline implementation which will enable broader patient access to innovative approaches in healthcare. Thethree parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. DoH seeks to drive research that will contribute...
PR Newswire
19/06/2023

Additional data from North American pivotal alfapump® study (POSEIDON) will be…

PRESS RELEASE Poster presentation at EASLby Dr. Florence Wong on 21 June 2023; selected for additional poster presentation on 23 June 2023Conference call withlive webcast by Sequana Medical on 21 June 2023 at 03:00 pm CEST / 09:00 am ESTGhent, Belgium – 19June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart...
Nasdaq GlobeNewswire
19/06/2023

Wirral University Teaching Hospital Modernizes Training with LMS365 on NHSmail…

"The work we've done at WUTH with NHS Digital (England) means that, following the usual procurement process, other Trusts should be able to easily implement the LMS365 solution into their own area of the NHSmail central tenant." - Paul Jones, Head of Clinical Applications " The work we've done at WUTH with NHS Digital ( England ) means that, following the usual procurement process, other Trusts should be able to easily implement the LMS365 solution into their own area of the…
PR Newswire
19/06/2023

Global Dental Tourism Market Anticipated to Garner $21,544.1 Million, Growing at…

As per the report published by Research Dive, the global dental tourism market is expected to register a revenue of $21,544.1 million by 2031 at a CAGR of 13.9% during the forecast period 2022-2031. As per the report published by Research Dive, theglobal dental tourism market is expected to register a revenue of$21,544.1 millionby 2031 at a CAGR of 13.9% during the forecast period 2022-2031. Segments of the Dental Tourism Market The report has divided the dental tourism...
PR Newswire
19/06/2023

HLTH Is Coming: Preeminent Health Innovation Event In The U.S. Launches In…

Weiner, who also co-founded industry-defining events Money20/20 and Shoptalk, said 'The last few years have shown that collaboration across healthcare is critical. From providers and payers , through patient groups and life sciences, to policy makers, startup founders and investors, now more than ever, healthcare must focus on solving the immediate challenges systems are facing. HLTH's events bring together the key players, at scale, to navigate the transformative opportunities that lie ahead…
PR Newswire
19/06/2023

Age-Related Macular Degeneration Market to Reach $15.4 Billion, Globally, by…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/3538 Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/3538 Prime determinants of growth The rising number of elderly individuals is a significant factor contributing to the growth of the age-related macular degeneration (AMD) market. With age, the likelihood of developing AMD substantially increases. This expanding elderly population represents a larger customer base for...
PR Newswire
19/06/2023

Hospital-At-Home Market to Record an Exponential CAGR by 2031 - Explained…

Home healthcare refers to a variety of medical therapies offered to address a patient's condition or injury in the convenience of their own home. Countless options are available to patients who want to get home health care. Depending on each patient's situation, care might range from nursing to specialized medical treatments, such as laboratory workups. Due to declining birth rates and rising life expectancy, the world's population is aging quickly. This could lead to a high frequency of chronic…
PR Newswire
19/06/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 19 June 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.Under the…
Nasdaq GlobeNewswire
19/06/2023

The ideal solution for every myopic child

If one of the parents is short-sighted, the child's risk of developing myopia is increased. If both parents are affected, the probability even increases to 35-60%. Myopia also tends to progress faster if the child's parents are myopic. Childhood myopia also increases the risk of eye disease in adulthood, irrespective of the severity. Controlling childhood myopia helps ensure healthier eyes in the long run, as the risk of developing eye diseases in adulthood is significantly reduced. As vision…
PR Newswire
19/06/2023

The ideal solution for every myopic child

If one of the parents is short-sighted, the child's risk of developing myopia is increased. If both parents are affected, the probability even increases to 35-60%. Myopia also tends to progress faster if the child's parents are myopic. Childhood myopia also increases the risk of eye disease in adulthood, irrespective of the severity. Controlling childhood myopia helps ensure healthier eyes in the long run, as the risk of developing eye diseases in adulthood is significantly reduced. As vision…
PR Newswire
19/06/2023

Freya Pharma Solutions Announces Response from the FDA on its US Clinical…

Dr. Jan van der Mooren, Chief Medical Officer at Freya Pharma Solutions said: Dr.Jan van der Mooren, Chief Medical Officer at Freya Pharma Solutions said: "The response from the FDA regarding Freya Pharma's clinical development program for Lybrido TMin the US fills me with optimism, as it suggests we are moving in the right direction to bring Lybrido TM to the market , and make a meaningful impact on the lives of numerous women affected by...
PR Newswire
19/06/2023

Novel Transcatheter Valve Repair Device: DRAGONFLY-DMR 12-Month Trial Results…

Background Background Severe Degenerative Mitral Regurgitation (DMR) is a prevalent heart valve disease that portends poor prognosis to patients if left untreated. Although surgical treatment is the gold standard for low surgical risk patients with DMR, a considerable number of patients worldwide remain undertreated due to high surgical risks or other factors. In recent years, TEER has emerged as the preferred technique for treating DMR in patients deemed high-risk for surgery, supported by...
PR Newswire
19/06/2023

The Summit Forum on the Application and Construction of AGP in China Takes Place…

As the co-sponsor, SiBionics also highlighted the great efforts and progress being made in the application and construction of AGP in China. As the co-sponsor, SiBionics also highlighted the great efforts and progress being made in the application and construction of AGP inChina. At this forum, Dr.Peng Can, Chief Scientific Officer of SiBionics, elaborated on the research program of SiBionics on AGP-based digital therapeutics. SiBionics is making sustained efforts in developing AGP...
PR Newswire
19/06/2023

Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of…

"We are delighted to welcome Jarl Ulf Jungnelius to the Board of Beactica Therapeutics," said Dr Per Källblad, CEO of Beactica Therapeutics. "His extensive experience in the corporate clinical development of life-changing oncology drugs will be valuable as Beactica accelerates its strategic plan to become a clinical-stage company." "We are delighted to welcome Jarl Ulf Jungnelius to the Board of Beactica Therapeutics," said DrPer Källblad, CEO of Beactica…
PR Newswire
19/06/2023

SciBase: Letter from the Chairman of the Board

The foremost priorities for SciBase are to focus on further improving US reimbursement of our products, to cover a larger population and geographical part of the US, improving sales and usage of the sold products in both the US and in Germany, as well as continue lowering the production cost in our products to enable future sales outside of these territories. The foremost priorities for SciBase are to focus on further improving US reimbursement ofourproducts, to cover a larger population...
PR Newswire
19/06/2023

Kindred and Dutch Matchis raise awareness for the need of stem cell donors

A stem cell transplant is the last chance for survival for hundreds of patients. Unfortunately, only 30 per cent of patients find a suitable donor in their family. It is, therefore, important that as many donors as possible are registered. A stem cell transplant is the last chance for survival for hundreds of patients. Unfortunately, only 30 per cent of patients find a suitable donor in their family. It is, therefore, important that as many donors as possible are registered. "This…
PR Newswire
19/06/2023

Mendus receives ATMP certificate from European Medicines Agency supporting its…

POSITIVE RECOMMENDATION BY COMMITTEE FOR ADVANCED THERAPIES CONFIRMS QUALITY OF THE MANUFACTURING PROCESS AND PRECLINICAL DATA SUBMITTEDMendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the company has been granted an Advanced Therapy Medicinal Product (ATMP) certificate following a review of manufacturing quality and non-clinical data for its lead pipeline program vididencel by the European...
Nasdaq GlobeNewswire
19/06/2023

BioSenic puts Phase IIb ALLOB trial on hold

INSIDE INFORMATION Prior efficacy unmatched but excellent safety profile confirmed, timing of ALLOB administration for optimal bone repair to be reevaluated Mont-Saint-Guibert, Belgium , June19 th 2023 , 7 .00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and bone and cartilage cell repair, today announces the decision to suspend its interventional trial on...
Nasdaq GlobeNewswire
19/06/2023

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma…

All patients in cohort 2 who were alive after 2 years remain alive after 3 yearsOslo, 19 June 2023:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced encouraging overall survival (OS) data from the cohort 2 in the UV1-103 Phase I clinical trial in malignant melanoma. All patients in cohort 2 who were alive at the 2-year follow-up, remain alive at the 3-year follow-up.The UV1-103 study evaluates...
Nasdaq GlobeNewswire
19/06/2023

First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring…

CAIX is a protein overexpressed on the surface of clear cell renal cell carcinoma (ccRCC), the cancer target in Telix's highly successful Phase III ZIRCON study.[3] It is also expressed to varying degrees in many other advanced-stage solid tumours with poor prognosis. Tumours that express CAIX are typically hypoxic, more aggressive and feature a tumour micro-environment (TME) that can be resistant to therapy, particularly immunotherapies. CAIX is a protein overexpressed on the surface of…
PR Newswire
19/06/2023

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of…

HOUSTON, June 17, 2023 /PRNewswire/ -- The result of clinical study for EUA (emergency use authorization) on COVID-19 with Xafty™ (CP-COV03) was presented at the 'Emerging Science' session of the American Society for Microbiology (ASM) Microbe 2023 conference, one of the largest conferences on infections and microbiology held in Houston, Texas, on June 17, 2023. Dr. Heungjeong Woo, a professor from Hallym University School of Medicine, South Korea, presented the meaning and expected effects from…
PR Newswire
17/06/2023

The 133rd Canton Fair: A New Coup to Cool Down and Escape from the Heat in this…

Guangzhou BKAI Imp & Exp Corp. Ltd. ("the Company") introduces the Cruise Ship, its innovative outdoor furniture on the Fair. The furniture boasts a unique design and practical features. Cruise Ship's innovative seating arrangement, enclosed on three sides and complemented by a front sunshade canopy, offers a functional and private outdoor space. The exquisite designs, including a lift-up bar, built-in ice bucket, and hidden storage space, create a cool and fresh atmosphere. For…
PR Newswire
17/06/2023

SHEIN LAUNCHES FIRST PRODUCT COLLABORATION UNDER EVOLUSHEIN BY DESIGN WITH…

"I am happy that SHEIN is taking an important step in sustainability and its overall environmental impact," said Anitta. "We all want to look great, while also respecting the planet and people." "I am happy that SHEIN is taking an important step in sustainability and its overall environmental impact," said Anitta. "We all want to look great, while also respecting the planet and people." The new collection showcases the three key environmentally focused…
PR Newswire
17/06/2023

Molfix Bond with Love Secure Attachment Bond Program was Honored with The…

Stating that they are proud and happy to receive another international award, Aysel Aydın, Hayat Global Vice President of Strategy and Marketing, said, "As part of the Bond with Love Secure Attachment Bond Program, which we have implemented in cooperation with the Ministry of Health General Directorate of Public Hospitals and the Infant Mental Health Association in 2019, we have embraced more than 160,000 parents and provided trainings on "Secure Attachment Bond" to nearly 3,000…
PR Newswire
17/06/2023
Altri  Comunicati